Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Redaktør Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pancreaskreft
  • Engelsk tittel -
  • Versjon - 4
  • Status - Publisert
  • IS-nr - 2559
  • ISBN - 978-82-8081-486-9
  • DOI -
  • Revisjonsdato - 01.03.2017
  • Neste revisjon -
  • Publikasjonsdato - 17.01.2014
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør - Jon Arne Søreide et al
  • Publikasjonstype - Nasjonale retningslinjer
Vedlegg
 
  1. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet 2016;388(10039):73–85.
  2. Søreide K, Aagnes B, Møller B, Westgaard A, Bray F. Epidemiology of pancreatic cancer in Norway: trends in incidence, basis of diagnosis and survival 1965–2007. Scand J Gastroenterol 2010;45(1):82–92.
  3. Bjerregaard JK, Mortensen MB, Schonnemann KR, Pfeiffer P. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer 2013;49(1):98–105.
  4. Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ 2012;344:e2476.
  5. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378(9791):607–20.
  6. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362(17):1605–17.
  7. Simianu VV, Zyromski NJ, Nakeeb A, Lillemoe KD. Pancreatic cancer: progress made. Acta Oncol 2010;49(4):407–17.
  8. Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, et al. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 2007;110(6):1227–34.
  9. Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63.
  10. Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208.
  11. Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C. Pancreatic surgery for adenocarcinoma. Curr Opin Gastroenterol 2012;28(5):488–93.
  12. Tol JA, van Gulik TM, Busch OR, Gouma DJ. Centralization of highly complex low-volume procedures in upper gastrointestinal surgery. A summary of systematic reviews and meta-analyses. Dig Surg 2012;29(5):374–83.
  13. van Heek NT, Kuhlmann KF, Scholten RJ, de Castro SM, Busch O, Rvan Gulik TM, et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg 2005;242(6):781–8.
  14. Alsamarrai A, Das SL, Windsor JA, Petrov MS. Factors that affect risk for pancreatic disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2014;12(10):1635–44.e5; quiz e103.
  15. Jiao L, Berrington de Gonzalez A, Hartge P, Pfeiffer RM, Park Y, Freedman DM, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control 2010;21(8):1305–14.
  16. Rebours V, Levy P, Ruszniewski P. An overview of hereditary pancreatitis. Dig Liver Dis 2012;44(1):8–15.
  17. Sakorafas GH, Tsiotos GG, Korkolis D, Smyrniotis V. Individuals at high-risk for pancreatic cancer development: Management options and the role of surgery. Surg Oncol 2012;21(2):e49–58.
  18. Solomon S, Whitcomb DC. Genetics of Pancreatitis: An Update for Clinicians and Genetic Counselors. Curr Gastroenterol Rep 2012;14(2):112–7.
  19. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011;47(13):1928–37.
  20. Peters ML, Tseng JF, Miksad RA. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clin Ther 2016;38(7):1622–35.
  21. Templeton AW, Brentnall TA. Screening and surgical outcomes of familial pancreatic cancer. Surg Clin North Am 2013;93(3):629–45.
  22. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257(1):17–26.
  23. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56(8):1134–52.
  24. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in Primary Care: A Systematic Review. Pancreas 2016;45(6):814–8.
  25. Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20(2):227–51.
  26. Horton KM, Fishman EK. Multidetector CT angiography of pancreatic carcinoma: part 2, evaluation of venous involvement. AJR Am J Roentgenol 2002;178(4):833–6.
  27. Horton KM, Fishman EK. Multidetector CT angiography of pancreatic carcinoma: part I, evaluation of arterial involvement. AJR Am J Roentgenol 2002;178(4):827–31.
  28. Perez-Johnston R, Lenhart DK, Sahani DV. CT angiography of the hepatic and pancreatic circulation. Radiol Clin North Am 2010;48(2):311–30, viii.
  29. Zhao WY, Luo M, Sun YW, Xu Q, Chen W, Zhao G, et al. Computed tomography in diagnosing vascular invasion in pancreatic and periampullary cancers: a systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int 2009;8(5):457–64.
  30. Wong JC, Raman S. Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging 2010;35(4):471–80.
  31. Kim JH, Park SH, Yu ES, Kim MH, Kim J, Byun JH, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010;257(1):87–96.
  32. Fusaroli P, Kypraios D, Eloubeidi MA, Caletti G. Levels of evidence in endoscopic ultrasonography: a systematic review. Dig Dis Sci 2012;57(3):602–9.
  33. Schima W, Ba-Ssalamah A, Kolblinger C, Kulinna-Cosentini C, Puespoek A, Gotzinger P. Pancreatic adenocarcinoma. Eur Radiol 2007;17(3):638–49.
  34. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology 2014;146(1):291–304.e1.
  35. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16(7):1727–33.
  36. Cascinu S, Falconi M, Valentini V, Jelic S. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v55–8.
  37. Majumder S, Chubineh S, Birk J. Pancreatic cancer: an endoscopic perspective. Expert Rev Gastroenterol Hepatol 2012;6(1):95–103.
  38. Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc 2012;75(2):319–31.
  39. Brugge W, Dewitt J, Klapman JB, Ashfaq R, Shidham V, Chhieng D, et al. Techniques for cytologic sampling of pancreatic and bile duct lesions. Diagn Cytopathol 2014;42(4):333–7.
  40. Madhoun MF, Wani SB, Rastogi A, Early D, Gaddam S, Tierney WM, et al. The diagnostic accuracy of 22-gauge and 25-gauge needles in endoscopic ultrasound-guided fine needle aspiration of solid pancreatic lesions: a meta-analysis. Endoscopy 2013;45(2):86–92.
  41. De Gaetano AM, Rufini V, Castaldi P, Gatto AM, Filograna L, Giordano A, et al. Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors. Abdom Imaging 2012;37(6):983–1003.
  42. Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol 2012;199(5):952–67.
  43. Pery C, Meurette G, Ansquer C, Frampas E, Regenet N. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol 2010;34(8–9):465–74.
  44. Thornton RH, Ulrich R, Hsu M, Moskowitz C, Reidy-Lagunes D, Covey AM, et al. Outcomes of patients undergoing percutaneous biliary drainage to reduce bilirubin for administration of chemotherapy. J Vasc Interv Radiol 2012;23(1):89–95.
  45. Amin Z, Theis B, Russell RC, House C, Novelli M, Lees WR. Diagnosing pancreatic cancer: the role of percutaneous biopsy and CT. Clin Radiol 2006;61(12):996–1002.
  46. Ishigami K, Yoshimitsu K, Irie H, Tajima T, Asayama Y, Hirakawa M, et al. Significance of perivascular soft tissue around the common hepatic and proximal superior mesenteric arteries arising after pancreaticoduodenectomy: evaluation with serial MDCT studies. Abdom Imaging 2008;33(6):654–61.
  47. Garcea G, Cairns V, Berry DP, Neal CP, Metcalfe MS, Dennison AR. Improving the diagnostic yield from staging laparoscopy for periampullary malignancies: the value of preoperative inflammatory markers and radiological tumor size. Pancreas 2012;41(2):233–7.
  48. Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg 2009;208(1):87–95.
  49. Slaar A, Eshuis WJ, van der Gaag NA, Nio CY, Busch OR, van Gulik TM, et al. Predicting distant metastasis in patients with suspected pancreatic and periampullary tumors for selective use of staging laparoscopy. World J Surg 2011;35(11):2528–34.
  50. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19‑9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012;3(2):105–19.
  51. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, et al. Serum CA 19‑9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010;17(7):1794–801.
  52. Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC. Preoperative CA 19‑9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol 2011;34(6):567–72.
  53. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24(33):5313–27.
  54. Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014;53(10):1284–97.
  55. Yang X, Yang Y, Li Z, Cheng C, Yang T, Wang C, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 2015;10(4):e0124884.
  56. Low G, Panu A, Millo N, Leen E. Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics 2011;31(4):993–1015.
  57. Fattahi R, Balci NC, Perman WH, Hsueh EC, Alkaade S, Havlioglu N, et al. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging 2009;29(2):350–6.
  58. Maillette de Buy Wenniger L, Rauws EA, Beuers U. What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree. Endoscopy 2012;44(1):66–73.
  59. Lee TY, Kim MH, Park do H, Seo DW, Lee SK, Kim JS, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 2009;193(2):343–8.
  60. Moon SH, Kim MH. The role of endoscopy in the diagnosis of autoimmune pancreatitis. Gastrointest Endosc 2012;76(3):645–56.
  61. Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut 2008;57(12):1704–12.
  62. Takuma K, Kamisawa T, Gopalakrishna R, Hara S, Tabata T, Inaba Y, et al. Strategy to differentiate autoimmune pancreatitis from pancreas cancer. World J Gastroenterol 2012;18(10):1015–20.
  63. Manzelli A, Petrou A, Lazzaro A, Brennan N, Soonawalla Z, Friend P. Groove pancreatitis. A mini-series report and review of the literature. JOP 2011;12(3):230–3.
  64. Sobin LH, Gospodarowicz M, Wettekind C, red. TNM: classification of malignant tumors. 7. utg. Oxford: Wiley-Blackwell; 2010.
  65. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 2011;254(6):882–93.
  66. Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998;85(5):611–7.
  67. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8(8):935–49.
  68. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 2012;36(4):884–91.
  69. Worni M, Castleberry AW, Clary BM, Gloor B, Carvalho E, Jacobs DO, et al. Concomitant Vascular Reconstruction During Pancreatectomy for Malignant Disease: A Propensity Score-Adjusted, Population-Based Trend Analysis Involving 10 206 Patients. JAMA Surg 2013;148: 331–8.
  70. Wang F, Arianayagam R, Gill A, Puttaswamy V, Neale M, Gananadha S, et al. Grafts for mesenterico-portal vein resections can be avoided during pancreatoduodenectomy. J Am Coll Surg 2012;215(4):569–79.
  71. Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg 2010;14(9):1442–52.
  72. Lee DY, Mitchell EL, Jones MA, Landry GJ, Liem TK, Sheppard BC, et al. Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy. J Vasc Surg 2010;51(3):662–6.
  73. Ohwada S, Hamada K, Kawate S, Sunose Y, Tomizawa N, Yamada T, et al. Left renal vein graft for vascular reconstruction in abdominal malignancy. World J Surg 2007;31(6):1215–20.
  74. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014;155(6):977–88.
  75. NCCN Clinical Practical Guidleines in Oncology: Pancreas Adenocarcinoma. Version 2. 2015. Washington, PA: National Comprehensive Cancer Network; 2015. Tilgjengelig fra: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (krever registrering)
  76. Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg 2015;220(4):530–6.
  77. Marangoni G, Morris-Stiff G, Deshmukh S, Hakeem A, Smith AM. A modern approach to teaching pancreatic surgery: stepwise pancreatoduodenectomy for trainees. J Gastrointest Surg 2012;16(8):1597–604.
  78. Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : Long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012;19(3):230–41.
  79. Datta J, Vollmer CM, Jr. Advances in Surgical Management of Pancreatic Diseases. Gastroenterol Clin North Am 2016;45(1):129–44.
  80. Dudekula A, Munigala S, Zureikat AH, Yadav D. Operative Trends for Pancreatic Diseases in the USA: Analysis of the Nationwide Inpatient Sample from 1998–2011. J Gastrointest Surg 2016;20(4):803–11.
  81. Hoem D, Viste A. Improving survival following surgery for pancreatic ductal adenocarcinoma--a ten-year experience. Eur J Surg Oncol 2012;38(3):245–51.
  82. Søreide JA, Sandvik OM, Søreide K. Improving pancreas surgery over time: Performance factors related to transition of care and patient volume. Int J Surg 2016;32:116–22.
  83. Westgaard A, Laronningen S, Mellem C, Eide TJ, Clausen OP, Moller B, et al. Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer 2009;45(16):2850–9.
  84. Assifi MM, Lindenmeyer J, Leiby BE, Grunwald Z, Rosato EL, Kennedy EP, et al. Surgical Apgar score predicts perioperative morbidity in patients undergoing pancreaticoduodenectomy at a high-volume center. J Gastrointest Surg 2012;16(2):275–81.
  85. Welsch T, Frommhold K, Hinz U, Weigand MA, Kleeff J, Friess H, et al. Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery 2008;143(1):20–8.
  86. Kunstman JW, Fonseca AL, Ciarleglio MM, Cong X, Hochberg A, Salem RR. Comprehensive analysis of variables affecting delayed gastric emptying following pancreaticoduodenectomy. J Gastrointest Surg 2012;16(7):1354–61.
  87. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138(1):8–13.
  88. Denbo JW, Orr WS, Zarzaur BL, Behrman SW. Toward defining grade C pancreatic fistula following pancreaticoduodenectomy: incidence, risk factors, management and outcome. HPB (Oxford) 2012;14(9):589–93.
  89. Correa-Gallego C, Brennan M, FD’Angelica M, IDeMatteo R, PFong, YKingham T, et al. Contemporary experience with postpancreatectomy hemorrhage: results of 1,122 patients resected between 2006 and 2011. J Am Coll Surg 2012;215(5):616–21.
  90. Roulin D, Cerantola Y, Demartines N, Schafer M. Systematic review of delayed postoperative hemorrhage after pancreatic resection. J Gastrointest Surg 2011;15(6):1055–62.
  91. Sanjay P, Kellner M, Tait IS. The role of interventional radiology in the management of surgical complications after pancreatoduodenectomy. HPB (Oxford) 2012;14(12):812–7.
  92. Eeson G, Chang N, McGahan CE, Khurshed F, Buczkowski AK, Scudamore CH, et al. Determination of factors predictive of outcome for patients undergoing a pancreaticoduodenectomy of pancreatic head ductal adenocarcinomas. HPB (Oxford) 2012;14(5):310–6.
  93. Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg Clin North Am 2001;81(3):543–55.
  94. Deshpande V, Konstantinidis IT, Castillo CF, Hezel AF, Haigis KM, Ting DT, et al. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 2016;20(5):953–9.
  95. Whipple AO, Parsons WB, Mullins CR. Treatment of Carcinoma of the Ampulla of Vater. Ann Surg 1935;102(4):763–79.
  96. Christians KK, Tsai S, Tolat PP, Evans DB. Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. J Surg Oncol 2013;107(1):33–8.
  97. Traverso LW, Longmire WP. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146(6):959–62.
  98. Huttner FJ, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Buchler MW, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2016;(2):CD006053.
  99. Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014;156(3):591–600.
  100. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138(4):618–28.
  101. Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007;94(3):265–73.
  102. Briggs C, DMann CD, Irving GR, Neal CP, Peterson M, Cameron IC, et al. Systematic review of minimally invasive pancreatic resection. J Gastrointest Surg 2009;13(6):1129–37.
  103. Zhou W, Lv R, Wang X, Mou Y, Cai X, Herr I. Stapler vs suture closure of pancreatic remnant after distal pancreatectomy: a meta-analysis. Am J Surg 2010;200(4):529–36.
  104. Fang Y, Gurusamy KS, Wang Q, Davidson BR, Lin H, Xie X, et al. Pre-operative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev 2012;(9):CD005444.
  105. Qiu YD, Bai JL, Xu FG, Ding YT. Effect of preoperative biliary drainage on malignant obstructive jaundice: a meta-analysis. World J Gastroenterol 2011;17(3):391–6.
  106. De Martino RR, Goodney PP, Spangler EL, Wallaert JB, Corriere MA, Rzucidlo EM, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg 2012;55(4):1035–40.
  107. Sudo T, Murakami Y, Uemura K, Hayashidani Y, Hashimoto Y, Ohge H, et al. Specific antibiotic prophylaxis based on bile cultures is required to prevent postoperative infectious complications in pancreatoduodenectomy patients who have undergone preoperative biliary drainage. World J Surg 2007;31(11):2230–5.
  108. Dominguez-Munoz JE. Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery. HPB (Oxford) 2009;11(Suppl 3):3–6.
  109. Sikkens EC, Cahen DL, van Eijck C, Kuipers EJ, Bruno MJ. The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: a northern European survey: enzyme replacement after surgery. J Gastrointest Surg 2012;16(8):1487–92.
  110. Connor S, Alexakis N, Garden OJ, Leandros E, Bramis J, Wigmore SJ. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005;92(9):1059–67.
  111. Lai E, CLau SH, Lau WY. Measures to prevent pancreatic fistula after pancreatoduodenectomy: a comprehensive review. Arch Surg 2009;144(11):1074–80.
  112. Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev 2010;(2):CD008370.
  113. Koti RS, Gurusamy KS, Fusai G, Davidson BR. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford) 2010;12(3):155–65.
  114. Diener MK, Mehr KT, Wente MN, Kieser M, Buchler MW, Seiler CM. Risk-benefit assessment of closed intra-abdominal drains after pancreatic surgery: a systematic review and meta-analysis assessing the current state of evidence. Langenbecks Arch Surg 2011;396(1):41–52.
  115. Kawai M, Tani M, Terasawa H, Ina S, Hirono S, Nishioka R, et al. Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for 104 consecutive patients. Ann Surg 2006;244(1):1–7.
  116. Søreide K, Labori KJ. Risk factors and preventive strategies for post-operative pancreatic fistula after pancreatic surgery: a comprehensive review. Scand J Gastroenterol 2016;51(10):1147–54.
  117. Berberat PO, Ingold H, Gulbinas A, Kleeff J, Muller MW, Gutt C, et al. Fast track--different implications in pancreatic surgery. J Gastrointest Surg 2007;11(7):880–7.
  118. Brennan MF, Pisters PW, Posner M, Quesada O, Shike M. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg 1994;220(4):436–41.
  119. Lassen K, Kjaeve J, Fetveit T, Trano G, Sigurdsson HK, Horn A, et al. Allowing normal food at will after major upper gastrointestinal surgery does not increase morbidity: a randomized multicenter trial. Ann Surg 2008;247(5):721–9.
  120. Lassen K, Ljungqvist O, Dejong CH, Demartines N, Parks RW, Lobo DN, et al. Pancreaticoduodenectomy: ERAS recommendations. Clin Nutr 2013;32(5):870–1.
  121. Bosman FT, Carneiro F, Hruben RH, Theise ND. WHO: Classification of Tumours of the Digestive System. 4 utg. Lyon: IARC; 2010.
  122. Chandrasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg 2015;102(12):1459–72.
  123. Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 2012;99(8):1036–49.
  124. Campell F, Verbeke CS. Pathology of the pancreas: a practical approach. London: Springer; 2013.
  125. Sobin LH, Gospodarwicz MK, Wittenkind CH, red. TNM: Classification of Malignant Tumors. 7. utg. Oxford: Wiley-Blackwell; 2010.
  126. Verbeke CS. Resection margins in pancreatic cancer. Surg Clin North Am 2013;93(3):647–62.
  127. Hruban RH, Klimstra DS. Adenocarcinoma of the pancreas. Semin Diagn Pathol 2014;31(6):443–51.
  128. Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, et al. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol 2015;39(12):1730–41.
  129. Yamasaki S, Suda K, Nobukawa B, Sonoue H. Intraductal spread of pancreatic cancer. Clinicopathologic study of 54 pancreatectomized patients. Pancreatology 2002;2(4):407–12.
  130. Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 2013;45(9):703–11.
  131. Fong ZV, Ferrone CR, Lillemoe KD, Fernandez-Del Castillo C. Intraductal Papillary Mucinous Neoplasm of the Pancreas: Current State of the Art and Ongoing Controversies. Ann Surg 2016;263(5):908–17.
  132. Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, et al. Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting. Ann Surg 2016;263(1):162–77.
  133. Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, et al. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Ann Surg Oncol 2011;18(12):3493–9.
  134. American College of Surgeons and the Alliance for Clinical Trials in Oncology, Nelson H, Hunt KK, Veeramachaneni N, Blair S, Chang G, et al., red. Operative Standards for Cancer Surgery: Volume 1: Breast, lung,pancreas, colon. Philadelphia: Walters Kluver; 2015.
  135. Verbeke CS, Gladhaug IP. Dissection of pancreatic specimens. Surg Pathol Clin Under publisering 2016.
  136. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011;15(11):2059–69.
  137. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350(12):1200–10.
  138. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3):267–77.
  139. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304(10):1073–81.
  140. Neoptolemos JP, Palmer DH, Ghaneh P, Valle JW, Cunningham D, Wadsley J, et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine and capecitabine versus monotherapy gemcitabine in patients with resected ductal adenocarcinoma. J Clin Oncol 2016;34(18 Suppl):LBA4006.
  141. Labori KJ, Verbeke CS, Gladhaug IP. Information needs among patients and a surveillance strategy after surgery for pancreatic and periampullary cancer. HPB (Oxford) 2015;17(7):659.
  142. Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, et al. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 2012;14(6):365–72.
  143. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 2015;15(1):8–18.
  144. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013;62(2):317–26.
  145. Conrad C, Lillemoe KD. Surgical palliation of pancreatic cancer. Cancer J 2012;18(6):577–83.
  146. Gillen S, Schuster T, Friess H, Kleeff J. Palliative resections versus palliative bypass procedures in pancreatic cancer–a systematic review. Am J Surg 2012;203(4):496–502.
  147. Gouma DJ, Nieveen van Dijkum EJ, van Geenen RC, van Gulik TM, Obertop H. Are there indications for palliative resection in pancreatic cancer? World J Surg 1999;23(9):954–9.
  148. Mann O, Strate T, Schneider C, Yekebas EF, Izbicki JR. Surgery for advanced and metastatic pancreatic cancer--current state and perspectives. Anticancer Res 2006;26(1B):681–6.
  149. Costamagna G, Pandolfi M. Endoscopic stenting for biliary and pancreatic malignancies. J Clin Gastroenterol 2004;38(1):59–67.
  150. Cote GA, Sherman S. Advances in pancreatobiliary endoscopy. Curr Opin Gastroenterol 2010;26(5):429–35.
  151. Larssen L, Medhus AW, Hjermstad MJ, Korner H, Glomsaker T, Soberg T, et al. Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study. Surg Endosc 2011;25(10):3162–9.
  152. Tol JA, van Hooft JE, Timmer R, Kubben FJ, van der Harst E, de Hingh IH, et al. Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut 2015.
  153. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006;(2):CD004200.
  154. Almadi MA, Barkun JS, Barkun AN. Stenting in Malignant Biliary Obstruction. Gastrointest Endosc Clin N Am 2015;25(4):691–711.
  155. Telford JJ, Carr-Locke DL, Baron TH, Tringali A, Parsons WG, Gabbrielli A, et al. Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study. Gastrointest Endosc 2004;60(6):916–20.
  156. Moss AC, Morris E, Leyden J, MacMathuna P. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 2007;19(12):1119–24.
  157. Larssen L, Medhus AW, Hauge T. Treatment of malignant gastric outlet obstruction with stents: an evaluation of the reported variables for clinical outcome. BMC Gastroenterol 2009;9:45.
  158. Gurusamy KS, Kumar S, Davidson BR. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev 2010;(10):CD008533.
  159. Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg 2011;15(11):1917–27.
  160. Campagnutta E, Cannizzaro R. Percutaneous endoscopic gastrostomy (PEG) in palliative treatment of non-operable intestinal obstruction due to gynecologic cancer: a review. Eur J Gynaecol Oncol 2000;21(4):397–402.
  161. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993;217(5):447–55.
  162. Strong VE, Dalal KM, Malhotra VT, Cubert KH, Coit D, Fong Y, et al. Initial report of laparoscopic celiac plexus block for pain relief in patients with unresectable pancreatic cancer. J Am Coll Surg 2006;203(1):129–31.
  163. Gress F, Schmitt C, Sherman S, Ikenberry S, Lehman G. A prospective randomized comparison of endoscopic ultrasound- and computed tomography-guided celiac plexus block for managing chronic pancreatitis pain. Am J Gastroenterol 1999;94(4):900–5.
  164. Kambadakone A, Thabet A, Gervais DA, Mueller PR, Arellano RS. CT-guided celiac plexus neurolysis: a review of anatomy, indications, technique, and tips for successful treatment. Radiographics 2011;31(6):1599–621.
  165. Akural E, Ojala RO, Jarvimaki V, Kariniemi J, Tervonen OA, Blanco Sequeiros R. MR-guided Neurolytic Celiac Plexus Ablation: An Evaluation of Effects and Injection Spread Pattern in Cancer Patients with Celiac Tumor Infiltration. Cardiovasc Intervent Radiol 2013;36(2):472–8.
  166. Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011;(3):CD007519.
  167. Loehrer PJ, SrFeng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011;29(31):4105–12.
  168. Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012;118(12):3026–35.
  169. McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev 2000;(2):CD001793.
  170. Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy – a systematic review of the randomised trials. Cochrane Database Syst Rev 2004;(2):CD004721.
  171. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997;33(Suppl 1):S18-S22.
  172. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403–13.
  173. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6(3):267–74.
  174. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81(6):882–5.
  175. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960–6.
  176. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817–25.
  177. Gounaris I, Zaki K, Corrie P. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP 2010;11(2):113–23.
  178. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691–703.
  179. Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. Oslo: Helsedirektoratet; 2014. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen
  180. Gärtner S, Kruger J, Aghdassi AA, Steveling A, Simon P, Lerch MM, et al. Nutrition in Pancreatic Cancer: A Review. Gastrointest Tumors 2016;2(4):195–202.
  181. Nordøy T, Thoresen L, Kvikstad A, Svensen R. Ernæring og væskebehandling til pasienter med ikke-kurabel kreftsykdom. Tidsskr Nor Lægeforen 2006;126(5):624–7.
  182. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12(5):489–95.
  183. Stewart GD, Skipworth RJ, Fearon KC. Cancer cachexia and fatigue. Clin Med 2006;6(2):140–3.
  184. Vashi P, Popiel B, Lammersfeld C, Gupta D. Outcomes of systematic nutritional assessment and medical nutrition therapy in pancreatic cancer. Pancreas 2015;44(5):750–5.
  185. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005;23(33):8500–11.
  186. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005;(2):CD004310.
  187. Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga G, et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr 2006;25(2):245–59.
  188. Plonk WM, Arnold RM. Terminal care: the last weeks of life. J Palliat Med 2005;8(5):1042–54.
  189. Good P, Cavenagh J, Mather M, Ravenscroft P. Medically assisted nutrition for palliative care in adult patients. Cochrane Database Syst Rev 2008;(4):CD006274.
  190. Dy SM. Enteral and parenteral nutrition in terminally ill cancer patients: a review of the literature. Am J Hosp Palliat Care 2006;23(5):369–77.
  191. Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartementet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf
  192. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30.
  193. Nasjonal strategi for kreftområdet 2006–2009. Oslo: Helse- og omsorgsdepartementet; 2006. Tilgjengelig fra: https://www.regjeringen.no/globalassets/upload/hod/sykehus/kreftstrategi-2006-2009.pdf